Inovio Pharmaceuticals (INO) Cut to “Sell” at BidaskClub

BidaskClub downgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a hold rating to a sell rating in a research report report published on Saturday morning, BidAskClub reports.

INO has been the subject of a number of other research reports. Maxim Group reissued a buy rating and set a $8.00 target price on shares of Inovio Pharmaceuticals in a report on Wednesday, April 3rd. HC Wainwright reissued a buy rating and set a $13.00 target price on shares of Inovio Pharmaceuticals in a report on Friday, March 22nd. Finally, Zacks Investment Research raised Inovio Pharmaceuticals from a hold rating to a buy rating and set a $5.25 target price for the company in a report on Thursday, February 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company currently has an average rating of Buy and an average price target of $7.57.

Shares of Inovio Pharmaceuticals stock traded down $0.08 during mid-day trading on Friday, reaching $3.34. 1,071,672 shares of the stock traded hands, compared to its average volume of 810,120. Inovio Pharmaceuticals has a fifty-two week low of $3.02 and a fifty-two week high of $6.30. The stock has a market capitalization of $327.43 million, a P/E ratio of -3.18 and a beta of 1.70. The company has a debt-to-equity ratio of 1.02, a current ratio of 4.92 and a quick ratio of 4.92.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Inovio Pharmaceuticals had a negative net margin of 295.24% and a negative return on equity of 97.95%. The firm had revenue of $2.83 million for the quarter, compared to analyst estimates of $4.44 million. As a group, research analysts anticipate that Inovio Pharmaceuticals will post -1.01 EPS for the current fiscal year.

In other news, CEO Jong Joseph Kim sold 136,768 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $3.50, for a total value of $478,688.00. Following the completion of the sale, the chief executive officer now directly owns 2,511,055 shares in the company, valued at $8,788,692.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.90% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new position in Inovio Pharmaceuticals in the first quarter worth approximately $40,000. Quantamental Technologies LLC purchased a new position in Inovio Pharmaceuticals in the fourth quarter worth approximately $43,000. Amalgamated Bank purchased a new position in Inovio Pharmaceuticals in the fourth quarter worth approximately $50,000. Pembroke Management LTD purchased a new position in Inovio Pharmaceuticals in the fourth quarter worth approximately $52,000. Finally, M Holdings Securities Inc. purchased a new position in Inovio Pharmaceuticals in the first quarter worth approximately $54,000. Institutional investors and hedge funds own 40.50% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Recommended Story: Price to Earnings Ratio (PE) Basics

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.